Valuation : Allergy Therapeutics plc

Market Cap 355M 482M 414M 388M 669M 45.97B 672M 4.59B 1.78B 23.19B 1.81B 1.77B 76.81B P/E 2026 *
-6.15x
P/E 2027 * -
Enterprise Value 399M 542M 465M 437M 753M 51.7B 756M 5.17B 2B 26.08B 2.04B 1.99B 86.39B EV / Sales 2026 *
6.66x
EV / Sales 2027 * -
Free-Float
11.23%
Yield 2026 *
-
Yield 2027 * -
1 day+2.14%
1 week+8.95%
Current month-4.35%
1 month+5.93%
3 months-37.14%
6 months-52.33%
Current year-48.00%
1 week 5.08
Extreme 5.075
6
1 month 5
Extreme 5
6.26
Current year 5
Extreme 5
12.1
1 year 5
Extreme 5
12.1
3 years 1.2
Extreme 1.2
12.1
5 years 0.8
Extreme 0.8
40.5
10 years 0.8
Extreme 0.8
40.5
Manager TitleAgeSince
Chief Executive Officer 62 01/09/2009
Director of Finance/CFO - 11/08/2023
Corporate Officer/Principal - 01/05/2013
Director TitleAgeSince
Director/Board Member 62 01/09/2009
Chairman 75 04/01/2011
Director/Board Member 69 06/06/2017
Date Insider Type Main position Quantity % Market Cap.
13/06/26 Free

Chief Financial Officer

2,300,000 0.0363%
12/03/26
ZQ Capital Ltd.
OthersCompany 1,993,473,455 32.4594%
12/03/26
ZQ Capital Ltd.
OthersCompany 150,925,926 2.4575%
Change 5-day change 1-year change 3-year change Capi.($)
+2.14%+8.95%-34.25%+100.70% 482M
-2.25%-3.10%+38.65%-1.87% 81.36B
-5.77%-14.18%+505.18%+33.71% 59.75B
+0.84%+4.44%-19.19%-35.11% 59.19B
+0.76%+3.53%+0.08%+36.18% 53.33B
+1.58%+2.98%+11.53%+173.06% 49.09B
+0.14%-0.22%+61.70%-16.40% 32.66B
-1.23%-0.27%+52.52%+100.63% 25.97B
-2.00%+6.32%+18.24%+209.64% 24.39B
+0.56%+0.17%+61.05%+122.73% 16.91B
Average -0.02%+0.81%+69.55%+72.33% 40.31B
Weighted average by Cap. -0.31%-1.00%+93.28%+48.43%

Financials

2026 *2027 *
Net sales 59.9M 81.41M 69.87M 65.58M 113M 7.76B 114M 776M 301M 3.92B 306M 299M 12.97B -
Net income -55.7M -75.7M -64.98M -60.99M -105M -7.22B -106M -722M -280M -3.64B -284M -278M -12.06B -
Net Debt 44.2M 60.07M 51.56M 48.39M 83.42M 5.73B 83.82M 573M 222M 2.89B 226M 221M 9.57B -
Logo Allergy Therapeutics plc
Allergy Therapeutics plc is a United Kingdom-based international commercial biotechnology company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum free immunotherapies that have the potential to cure disease. It sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional 10 countries. It sells both injectable and sublingual (oral) allergen-specific immunotherapies. Its pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. Its therapies are traded under various brand names depending on the market, such as Pollinex Quattro, Polligoid and TA Graser Top. Its commercial products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics and Acarovac Plus. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL, and VLP Peanut.
Employees
584
Date Price Change Volume
27/08/26 GBX 5.720 +2.14% 17,412
26/08/26 GBX 5.600 0.00% 140,852
25/08/26 GBX 5.600 0.00% 81,941
24/08/26 GBX 5.600 +9.80% 37,516
21/08/26 GBX 5.100 -2.86% 443,733
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0560GBP
Average target price
0.1300GBP
Spread / Average Target
+132.14%

Annual profits - Rate of surprise